Cara Therapeutics Net Income 2012-2021 | CARA

Cara Therapeutics net income from 2012 to 2021. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
Cara Therapeutics Annual Net Income
(Millions of US $)
2020 $8
2019 $-106
2018 $-74
2017 $-58
2016 $-57
2015 $-25
2014 $-18
2013 $-3
2012 $-6
2011 $-10
Cara Therapeutics Quarterly Net Income
(Millions of US $)
2021-09-30 $-1
2021-06-30 $-31
2021-03-31 $-23
2020-12-31 $79
2020-09-30 $-17
2020-06-30 $-25
2020-03-31 $-29
2019-12-31 $-29
2019-09-30 $-33
2019-06-30 $-23
2019-03-31 $-22
2018-12-31 $-21
2018-09-30 $-19
2018-06-30 $-17
2018-03-31 $-17
2017-12-31 $-14
2017-09-30 $-12
2017-06-30 $-9
2017-03-31 $-22
2016-12-31 $-22
2016-09-30 $-12
2016-06-30 $-13
2016-03-31 $-11
2015-12-31 $-10
2015-09-30 $-5
2015-06-30 $-6
2015-03-31 $-5
2014-12-31 $-4
2014-09-30 $-7
2014-06-30 $-4
2014-03-31 $-3
2013-12-31 $2
2013-09-30 $-5
2013-06-30 $1
2013-03-31 $-2
2012-12-31
2012-09-30
2011-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.639B $0.135B
Cara Therapeutics, Inc. is a biopharmaceutical company. The company is focused on developing and commercializing new chemical entities designed to alleviate pain. Cara Therapeutics, Inc. is based in Shelton, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $144.122B 9.11
Bio-Rad Laboratories (BIO.B) United States $18.677B 37.90
QIAGEN (QGEN) Netherlands $11.053B 18.72
Biohaven Pharmaceutical Holding (BHVN) United States $8.002B 0.00
Emergent Biosolutions (EBS) United States $2.809B 10.10
Arcus Biosciences (RCUS) United States $2.516B 0.00
Myovant Sciences (MYOV) United Kingdom $1.432B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.186B 0.00
Zymeworks (ZYME) Canada $0.697B 0.00
Ambrx Biopharma (AMAM) United States $0.230B 0.00
SQZ Biotechnologies (SQZ) United States $0.229B 0.00
Enzo Biochem (ENZ) United States $0.160B 20.69